Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (338)

2024

  1. A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort

    Schizophrenia Research, Vol. 266, pp. 237-248

  2. Apolipoprotein E-ϵ2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study

    Circulation Research, Vol. 134, Núm. 4, pp. 411-424

  3. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  4. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

  5. Deep Brain Stimulation for Obsessive-Compulsive Disorder: Optimal Stimulation Sites

    Biological Psychiatry

  6. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  7. Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study

    Molecular Psychiatry

  8. Oral anticoagulants: A plausible new treatment for Alzheimer's disease?

    British Journal of Pharmacology, Vol. 181, Núm. 6, pp. 760-776

  9. PsyCog: A computerised mini battery for assessing cognition in psychosis

    Schizophrenia Research: Cognition, Vol. 37

  10. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis

    The Lancet Psychiatry, Vol. 11, Núm. 1, pp. 36-46

  11. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

  3. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  4. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

    International Journal of Cardiology, Vol. 383, pp. 24-32

  5. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

  6. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: Results from the EU-GEI case-control study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7375-7384

  7. Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis

    Diabetes Care, Vol. 46, Núm. 11, pp. 2050-2057

  8. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 13, pp. 6150-6160

  9. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

    American Journal of Cardiology, Vol. 208, pp. 16-24